Abstract 70P
Background
The efficacy and safety of the three-drug combination of eribulin (E), trastuzumab (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) as first-line treatment was reported. The overall response rate (complete response [CR] + partial response [PR]) was 80.0% (95% confidence interval [CI], 59.3–93.2%), and the clinical benefit rate (CR + PR + stable disease ≥24 weeks; CBR) was 84.0% (95% CI, 63.9–95.5%). Median time to treatment failure with E was 9.1 months (95% CI, 4.3–13.9 months), and median progression-free survival was 23.1 months (95% CI, 14.4–31.8 months). The most common treatment-emergent adverse events (TEAEs) were alopecia (92.0%), fatigue (68.0%), and sensory peripheral neuropathy (60.0%). Grade 3/4 TEAEs occurred in 11 patients (44.0%). The only grade 4 TEAE was neutrophil count decreased (16.0%). Neither grade 4 peripheral neuropathy nor febrile neutropenia occurred (Inoue K et al Investigational New Drugs 2019; 180:135–46). We report the overall survival results and the efficacy of post-ETP treatments at 5.5 years after the last enrollment.
Methods
E 1.4 mg/m2 (days 1 and 8), T 8 mg/kg over 90 min and 6 mg/kg over 30 min, and P 840 mg/body over 60 min and 420 mg/body over 30 min were administered intravenously in 21-day cycles.
Results
From April 2016 to November 2017, 25 women received ETP therapy and 12 of the 25 survived with a median OS of 78.4 months, 95% CI 26.4-NA months. Subset analysis by log-rank test showed a significant difference (P=0.0114) and hazard ratio; 3.063 95% CI 1.002-9.361 in hemoglobulin (≥12 vs. ≤12 mg/dl), but not in estrogen receptor status and neutrophil/lymphocyte ratio (≥2 vs. <2). T-emtansine, capecitabine + TP, T-deruxtecan, and epirubicin + cyclophosphamide were administered after ETP with CBR of 72.2% (13/18 patients), 80.0% (4/5 patients), 66.7% (2/3 patients) and 33.3% (1/3 patients), respectively.
Conclusions
ETP therapy showed acceptable efficacy and overall survival as first-line therapy for patients with HER2-positive Japanese MBC.
Clinical trial identification
UMIN000021585.
Editorial acknowledgement
Legal entity responsible for the study
Saitama breast cancer clinical study group.
Funding
Has not received any funding.
Disclosure
K. Inoue: Financial Interests, Institutional, Funding: AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa-Kirin, MSD, Novartis, Pfizer, Taiho, Ono, Astellas, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract